Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2025 · 10-Q
Revenue$31.12M$31.12M+36.8% vs Q2 2024 Net Income$3.61M$3.61MN/M vs Q2 2024 EPS Diluted$0.04$0.04— vs Q2 2024 Gross Profit$20,226,000+47.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,250,000N/M Margins · derivedGross margin65.0%+4.8 pt vs Q2 2024
Operating margin10.2%+11.4 pt vs Q2 2024
Net margin11.6%+11.7 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 6, 2025 · 37 d after period end